{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:19:11Z","timestamp":1793909951977,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Netherlands Association for Scientific Research","award":["Spinoza Grant"],"award-info":[{"award-number":["Spinoza Grant"]}]},{"name":"European Research Council","award":["833247"],"award-info":[{"award-number":["833247"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune checkpoint inhibitors have revolutionized therapy of advanced and metastatic cancers. However, a significant proportion of patients do not respond to immune checkpoint inhibitors or develop resistance. Therefore, novel therapies or combinations of therapies that may act synergistically are needed. It has been suggested that induction of trained immunity may increase the response to immune checkpoint inhibitor therapy, through reprogramming myeloid cells toward an antitumor phenotype. On the other hand, activation of the immune system also carries the risk of potentially sustaining tumorgenicity and increasing immune- related toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report the case of a 37-year-old Dutch male suffering from gastric neuroendocrine carcinoma with liver metastases and high risk for an unfavorable outcome, who was treated with a combination of programmed cell death protein 1 inhibitor nivolumab and the trained immunity-inducer Bacillus Calmette\u2013Gu\u00e9rin vaccine as a salvage therapy. Three doses of BCG vaccine were administered at 3-month intervals, in conjunction with the immune checkpoint inhibitor regimen. At a certain point, radiation therapy was added to the treatment regimen. During the combination of these therapies, the patient developed immune-mediated colitis, which necessitated discontinuation of all treatments. Bacillus Calmette\u2013Gu\u00e9rin vaccination induced a trained immune response with elevated monocyte-derived interleukin-6 and interleukin-1\u03b2 production capacity. From the first vaccination with Bacillus Calmette\u2013Gu\u00e9rin until 3\u00a0months after the last vaccination with Bacillus Calmette\u2013Gu\u00e9rin, the patient displayed only mild progression of the primary tumor and no progression of the metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, we show the feasibility to combine checkpoint inhibitor therapy with inducers of trained immunity in a patient with an aggressive neuroendocrine tumor. Autoimmune side effects are common under programmed cell death protein 1 inhibitor therapy, which was considered the most likely cause of colitis, although an additive effect of Bacillus Calmette\u2013Gu\u00e9rin vaccination or radiotherapy cannot be excluded. The patient displayed only mild progression during the combination therapy, but larger studies are warranted to fully explore the potential benefit of trained immunity inducers as an adjuvant to immune checkpoint inhibitor therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04117-3","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:02:22Z","timestamp":1693785742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the safety and immunological effects of Bacillus Calmette\u2013Gu\u00e9rin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-6943","authenticated-orcid":false,"given":"Konstantin","family":"F\u00f6hse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya A.","family":"Debisarun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"van Dodewaard-de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"4","key":"4117_CR1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934\u201359.","journal-title":"Cancer"},{"issue":"18","key":"4117_CR2","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et\u00a0al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4117_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"11","key":"4117_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"4117_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","volume":"9","author":"Y Yan","year":"2018","unstructured":"Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, et\u00a0al. Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol. 2018;9:1739.","journal-title":"Front Immunol"},{"issue":"17","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et\u00a0al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 2018;115(17):E4041\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"4117_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati L, Kourtzelis I, Schulte-Schrepping J, Li X, Hatzioannou A, Grinenko T, et\u00a0al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-85 e12.","journal-title":"Cell"},{"issue":"3","key":"4117_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cell.2020.09.059","volume":"183","author":"B Priem","year":"2020","unstructured":"Priem B, van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, et\u00a0al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell. 2020;183(3):786-801 e12.","journal-title":"Cell"},{"issue":"5","key":"4117_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/vaccines9050439","volume":"9","author":"F Cardillo","year":"2021","unstructured":"Cardillo F, Bonfim M, Vasconcelos Sousa P, Mengel J, Ribeiro Castello-Branco LR, Pinho RT. Bacillus Calmette-Guerin immunotherapy for cancer. Vaccines (Basel). 2021;9(5):439.","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et\u00a0al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375\u201388.","journal-title":"Nat Rev Immunol"},{"key":"4117_CR12","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3389\/fmicb.2019.02924","volume":"10","author":"JR Lerias","year":"2019","unstructured":"Lerias JR, de Sousa E, Paraschoudi G, Martins J, Condeco C, Figueiredo N, et\u00a0al. Trained immunity for personalized cancer immunotherapy: current knowledge and future opportunities. Front Microbiol. 2019;10:2924.","journal-title":"Front Microbiol"},{"issue":"50","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"7332","DOI":"10.1016\/j.vaccine.2021.09.053","volume":"39","author":"N Mukherjee","year":"2021","unstructured":"Mukherjee N, Julian E, Torrelles JB, Svatek RS. Effects of Mycobacterium bovis Calmette et Guerin (BCG) in oncotherapy: bladder cancer and beyond. Vaccine. 2021;39(50):7332\u201340.","journal-title":"Vaccine"},{"issue":"6","key":"4117_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1189\/jlb.5RI0217-064RR","volume":"102","author":"MG Netea","year":"2017","unstructured":"Netea MG, Joosten LAB, van der Meer JWM. Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. J Leukoc Biol. 2017;102(6):1323\u201332.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"4117_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","volume":"11","author":"A Hou","year":"2020","unstructured":"Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front Immunol. 2020;11:783.","journal-title":"Front Immunol"},{"issue":"3","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/OP.22.00733","volume":"19","author":"M Houshyari","year":"2023","unstructured":"Houshyari M, Taghizadeh-Hesary F. Is Mitochondrial metabolism a new predictive biomarker for antiprogrammed cell death protein-1 immunotherapy? JCO Oncol Pract. 2023;19(3):123\u20134.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"4117_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","volume":"115","author":"E Bellaguarda","year":"2020","unstructured":"Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020;115(2):202\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4117_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/JLB.MR0318-104R","volume":"105","author":"J Dominguez-Andres","year":"2019","unstructured":"Dominguez-Andres J, Netea MG. Long-term reprogramming of the innate immune system. J Leukoc Biol. 2019;105(2):329\u201338.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","volume":"144","author":"A Bohle","year":"1990","unstructured":"Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990;144(1):53\u20138.","journal-title":"J Urol"},{"key":"4117_CR21","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","volume":"10","author":"C Covian","year":"2019","unstructured":"Covian C, Fernandez-Fierro A, Retamal-Diaz A, Diaz FE, Vasquez AE, Lay MK, et\u00a0al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front Immunol. 2019;10:2806.","journal-title":"Front Immunol"},{"issue":"1","key":"4117_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00294021","volume":"19","author":"EC de Boer","year":"1991","unstructured":"de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, et\u00a0al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res. 1991;19(1):45\u201350.","journal-title":"Urol Res"},{"issue":"6","key":"4117_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147(6):1636\u201342.","journal-title":"J Urol"},{"issue":"1","key":"4117_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1442-2042.2002.00415.x","volume":"9","author":"N Ikeda","year":"2002","unstructured":"Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells. Int J Urol. 2002;9(1):29\u201335.","journal-title":"Int J Urol"},{"key":"4117_CR25","doi-asserted-by":"publisher","first-page":"4048235","DOI":"10.1155\/2016\/4048235","volume":"2016","author":"L Chavez-Galan","year":"2016","unstructured":"Chavez-Galan L, Vesin D, Martinvalet D, Garcia I. Low dose BCG infection as a model for macrophage activation maintaining cell viability. J Immunol Res. 2016;2016:4048235.","journal-title":"J Immunol Res"},{"issue":"2","key":"4117_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","volume":"48","author":"LA Sena","year":"2012","unstructured":"Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158\u201367.","journal-title":"Mol Cell"},{"issue":"2","key":"4117_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","volume":"8","author":"MS Anscher","year":"2022","unstructured":"Anscher MS, Arora S, Weinstock C, Amatya A, Bandaru P, Tang C, et\u00a0al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database. JAMA Oncol. 2022;8(2):232\u201340.","journal-title":"JAMA Oncol"},{"issue":"30","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.19.00320","volume":"37","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, et\u00a0al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37(30):2738\u201345.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4117_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148291","volume":"131","author":"AK Singh","year":"2021","unstructured":"Singh AK, Netea MG, Bishai WR. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. J Clin Invest. 2021;131(11): e148291.","journal-title":"J Clin Invest"},{"issue":"8","key":"4117_CR30","first-page":"358","volume":"17","author":"JG Hashash","year":"2021","unstructured":"Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol (NY). 2021;17(8):358\u201366.","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"6","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063\u201378.","journal-title":"Retina"},{"issue":"1","key":"4117_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-020-00278-0","volume":"6","author":"J Li","year":"2021","unstructured":"Li J, Zhan L, Qin C. The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine. NPJ Vaccines. 2021;6(1):14.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"4117_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","volume":"29","author":"ER Dow","year":"2021","unstructured":"Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2021;29(1):203\u201311.","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"4117_CR34","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346\u201353.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4117_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"3","key":"4117_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et\u00a0al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374\u20138.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4117_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s11938-019-00263-0","volume":"17","author":"T Menon","year":"2019","unstructured":"Menon T, Afzali A. Immune-mediated colitis. Curr Treat Options Gastroenterol. 2019;17(4):506\u201323.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"4117_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147\u201364.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04117-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:29:43Z","timestamp":1700404183000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04117-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04117-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived because BCG was given as salvage therapy. The patient gave written informed consent using our institutional consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MGN is a scientific founder of TTxD, Lemba and BioTRIP.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}